Germany · Delayed Price · Currency is EUR Diamyd Medical AB Statistics
Total Valuation
FRA:DMN has a market cap or net worth of EUR 125.76 million. The enterprise value is 100.51 million.
| Market Cap | 125.76M |
| Enterprise Value | 100.51M |
Important Dates
The next estimated earnings date is Wednesday, January 28, 2026.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 134.00M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +18.81% |
| Shares Change (QoQ) | +29.83% |
| Owned by Insiders (%) | 13.09% |
| Owned by Institutions (%) | 25.08% |
| Float | 117.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 21.57 |
| PS Ratio | 10,722.15 |
| PB Ratio | 4.98 |
| P/TBV Ratio | 4.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.56 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.20 |
Financial Position
The company has a current ratio of 10.64
| Current Ratio | 10.64 |
| Quick Ratio | 10.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -79.72% and return on invested capital (ROIC) is -53.78%.
| Return on Equity (ROE) | -79.72% |
| Return on Assets (ROA) | -40.21% |
| Return on Invested Capital (ROIC) | -53.78% |
| Return on Capital Employed (ROCE) | -56.35% |
| Revenue Per Employee | 301 |
| Profits Per Employee | -392,768 |
| Employee Count | 39 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.89% |
| 50-Day Moving Average | 0.92 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 61.23 |
| Average Volume (20 Days) | 23 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:DMN had revenue of EUR 11,729 and -15.32 million in losses. Loss per share was -0.14.
| Revenue | 11,729 |
| Gross Profit | -334,280 |
| Operating Income | -16.53M |
| Pretax Income | -15.32M |
| Net Income | -15.32M |
| EBITDA | -15.95M |
| EBIT | -16.53M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 25.01 million in cash and n/a in debt, giving a net cash position of 25.01 million.
| Cash & Cash Equivalents | 25.01M |
| Total Debt | n/a |
| Net Cash | 25.01M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 25.26M |
| Book Value Per Share | 0.18 |
| Working Capital | 23.90M |
Cash Flow
In the last 12 months, operating cash flow was -15.31 million and capital expenditures -906,571, giving a free cash flow of -16.22 million.
| Operating Cash Flow | -15.31M |
| Capital Expenditures | -906,571 |
| Free Cash Flow | -16.22M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -140,950.76% |
| Pretax Margin | -130,599.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:DMN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.81% |
| Shareholder Yield | -18.81% |
| Earnings Yield | -12.18% |
| FCF Yield | -12.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |